PLUR: Pluri Inc. Stock

by  •  • Comments Off on PLUR: Pluri Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 27.30
Enterprise Value ($M) 48.45
Book Value ($M) 6.62
Book Value / Share 1.27
Price / Book 4.13
NCAV ($M) -2.69
NCAV / Share -0.52
Price / NCAV -10.13

Profitability (mra)
Return on Invested Capital (ROIC) -0.65
Return on Assets (ROA) -0.43
Return on Equity (ROE) -1.15

Liquidity (mrq)
Quick Ratio 7.12
Current Ratio 7.12

Balance Sheet (mrq) ($M)
Current Assets 32.25
Assets 41.56
Liabilities 34.95
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-13 13G/A Shayna LP 8.10
02-01 13G/A Slager David Mark 6.70 21.95

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-02-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 ☐ TRANSITION REPORT UNDE
2023-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT UND
2023-09-12 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT T
2023-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT UNDER S

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-26 1,551 1,479 104.87
2024-04-25 1,662 1,193 139.31
2024-04-24 1,931 7,297 26.46
2024-04-23 2,481 1,422 174.47
2024-04-22 4,185 2,206 189.71

(click for more detail)

Similar Companies
PDSB – PDS Biotechnology Corporation PHIO – Phio Pharmaceuticals Corp.
PIRS – Pieris Pharmaceuticals, Inc. PMCB – PharmaCyte Biotech, Inc.
PMGM – Priveterra Acquisition Corp. II


Financial data and stock pages provided by
Fintel.io